Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Malignant lymphoma].

S Shirakawa1, T Kobayashi, K Kita

  • 12nd Dept. of Internal Medicine, Faculty of Medicine, Mie University.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of <i>TP53</i> status in gemcitabine plus nab-paclitaxel therapy.

ESMO gastrointestinal oncology·2026
Same author

Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings.

ESMO open·2025
Same author

Histomorphological changes in the ileal mucosa in secondary amyloidosis.

QJM : monthly journal of the Association of Physicians·2021
Same author

Sequentially addressable dielectrophoretic array for high-throughput sorting of large-volume biological compartments.

Science advances·2020
Same author

Randomized, double-blind, placebo-controlled study vs data in the daily practice using linaclotide in patients with irritable bowel syndrome with constipation.

Neurogastroenterology and motility·2018
Same author

Rikkunshito simultaneously improves dyspepsia correlated with anxiety in patients with functional dyspepsia: A randomized clinical trial (the DREAM study).

Neurogastroenterology and motility·2018

Malignant lymphoma, including Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL), shows distinct characteristics in Japan. Advances in molecular diagnostics and multidisciplinary treatments, including novel chemotherapy regimens and biologics, are improving cure rates for lymphoma patients.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Context:

  • Malignant lymphoma classification into Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
  • Distinct epidemiological features of lymphoma in Japan compared to Western countries, including lower HD incidence and higher rates of unfavorable NHL subtypes.
  • Emerging trends in lymphoma research and treatment.

Purpose:

  • To provide an overview of the biological characteristics and epidemiological features of malignant lymphoma in Japan.
  • To highlight the diagnostic advancements in molecular biology for lymphoma.
  • To summarize recent progress in the multidisciplinary treatment of malignant lymphoma.

Summary:

  • Malignant lymphoma is broadly categorized into HD and NHL, with Japan exhibiting unique epidemiological patterns.

Related Experiment Videos

  • Molecular diagnostics, such as gene rearrangement analysis, are crucial for determining cell lineage and monoclonality.
  • Significant advancements in chemotherapy, radiotherapy, and immunotherapy have led to improved prognoses and potential cures, even in advanced cases.

    • Impact:

    • Improved diagnostic accuracy through molecular techniques.
    • Enhanced treatment strategies leading to better survival rates and potential cures for lymphoma.
    • Foundation for developing novel, targeted therapies and personalized treatment approaches for malignant lymphoma.